Effects of liquid and freeze-dried grapefruit juice on the pharmacokinetics of praziquantel and its metabolite 4′-hydroxy praziquantel in beagle dogs

Pharmacological Research

Volumn 47, Issue 1, 2003, Pages 87-92

  Giorgi, M ^a   Meucci, V ^a   Vaccaro, E ^a   Mengozzi, G ^a   Giusiani, M ^a   Soldani, G ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

4 Hydroxy praziquantel; Beagle dogs; Grapefruit juice; Praziquantel

Indexed keywords

4' HYDROXYPRAZIQUANTEL; DRUG METABOLITE; PRAZIQUANTEL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG DETERMINATION; FREEZE DRYING; GRAPEFRUIT JUICE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BEVERAGES; CITRUS PARADISI; DOGS; FREEZE DRYING; MALE; PRAZIQUANTEL;

EID: 0037282473     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-6618(02)00251-7     Document Type: Article

References (45)

1. Kane C., Lipsky J. Drug grapefruit juice interactions. Mayo Clin. Proc. 75:2000;933-942.
2. He K., Iyer K.R., Hayes R.N., Sinz M.W., Woolf T.F., Hollenberg P.F. Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice. Chem. Res. Toxicol. 11:1998;252-259.
3. Fukuda K., Ohta T., Ohshima Y., Ohashi N., Yoshikawa M., Yamazoe Y. Specific CYP3A4 inhibitors in grapefruit juice: furocumarin dimers as components of drug interaction. Pharmacogenetics. 7:1997;391-396.
4. Guo L.-Q., Fukuda K., Ohta T., Yamazoe Y. Role of furanocumarin derivatives on grapefruit juice-mediated inhibition of human CYP3A activity. Drug Metab. Dispos. 28:2000;766-771.
5. Lown K.S., Bailey D.G., Fontana R.J., Janardan S.K., Adair C.H., Fortlage L.A.et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J. Clin. Invest. 99:1997;2545-2553.
6. Kupferschmidt H.H.T., Ha H.R., Ziegler W.H., Meier P.J., Krahenbuhl S. Interaction between grapefruit juice and midazolam in human. Clin. Pharmacol. Ther. 58:1995;20-28.
7. Kupferschmidt H.H.T., Fattinger K.E., Ha H.R., Follath F., Krahenbuhl S. Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. Br. J. Clin. Pharmacol. 45:1998;355-359.
8. Lundahl J., Regardh C.G., Edgar B., Johnsson G. Effects of grapefruit juice ingestion-pharmacokinetics and haemodynamics of intravenously and orally administered felodipine in healthy men. Eur. J. Clin. Pharmacol. 52:1997;139-145.
9. Rashid T.J., Martin U., Clarke H., Waller D.G., Renwick A.G., George C.F. Factors affecting the absolute bioavailability of nifedipine. Br. J. Clin. Pharmacol. 40:1995;51-58.
10. Rogers J.D., Zhao J., Liu L.D., Amin R.D., Gagliano K.D., Porras A.G.et al. Grapefruit juice has minimal effects on plasma concentrations of lovastatin-derived 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Clin. Pharmacol. Ther. 66:1999;358-366.
11. Veronese M., Burke J., Dorval E., Pequignot E., Waldman S., Greenberg H. Grapefruit juice (GFJ) inhibits hepatic and intestinal CYP3A4 dose-dependently. Clin. Pharmacol. Ther. 67:2000;151. [Abstract PIII-37].
12. Ho P.C., Saville D.J. Inhibition of human CYP3A4 activity by grapefruit flavonoids, furanocoumarins and related compounds. J. Pharm. Pharm. Sci. 4:2001;217-227.
13. Maskalyk J. Grapefruit juice: potential drug interactions. Can. Med. Assoc. J. 167:2002;279-280.
14. Andrews P., Thomas H., Pohlke R., Seubert J. Praziquantel. Med. Res. Rev. 3:1983;147-200.
15. Morris D.L., Richards K.S., Clarkson M.J., Taylor D.H. Comparison of albendazole and praziquantel therapy of Echinococcus granulosus in naturally infected sheep. Vet. Parasitol. 36:1990;83-90.
16. Groll E. Praziquantel for cestode infections in man. Acta Trop. 37:1980;293-296.
17. Botero D., Castano S. Treatment of cysticercosis with praziquantel in Colombia. Am. J. Trop. Med. Hyg. 31:1982;811-821.
18. Steiner K., Garbe A., Diekmann H.W., Nowak H. The fate of praziquantel in the organism I. Pharmacokinetics in animals. Eur. J. Drug. Metab. Pharmacokinet. 2:1976;85-95.
19. Groll E. Praziquantel. Adv. Pharmacol. Chemother. 20:1984;219-238.
20. Giorgi M., Salvatori A.P., Soldani G., Giusiani M., Longo V., Gervasi P.G.et al. Pharmacokinetics and microsomal oxidation of praziquantel and its effects on the P450 system in 3-month-old lambs infested by Fasciola hepatica. J. Vet. Pharmacol. Ther. 24:2001;251-259.
21. Frohberg H. Results of toxicological studies on praziquantel. Arzneimittel-forsch. 34:1984;1137-1144.
22. Vazquez M.L., Jung H., Sotelo J. Plasma levels of praziquantel decrease when dexamethasone is given simultaneously. Neurology. 37:1987;1561-1562.
23. Bittencourt P.R., Gracia C.M., Martins R., Fernandes A.G., Diekmann H.W., Jung W. Phenytoin and carbamazepine decreased oral bioavailability of praziquantel. Neurology. 42:1992;492-496.
24. Masimirembwa C.M., Naik Y.S., Hasler J.A. Effect of phenobarbital and 3-methylcholanthrene pre-treatment on the pharmacokinetics of praziquantel in rats. Eur. J. Drug. Metab. Pharmacokinet. 18:1993;261-264.
25. Masimirembwa C.M., Hasler J.A. Characterisation of praziquantel metabolism by rat liver microsomes using cytochrome P450 inhibitors. Biochem. Pharmacol. 48:1994;1779-1783.
26. Castro N., Jung H., Medina R., Gonzalez-Esquivel D., Lopez M., Sotelo J. Interaction between grapefruit juice and praziquantel in humans. Antimicrob. Agents Chemother. 46:2002;1614-1616.
27. Xiao S.H., Catto B.A., Webster L.T. Quantitative determination of praziquantel in serum by high-performance liquid chromatography. J. Chromatogr. 275:1983;127-132.
28. Bailey D.G., Spence J.D., Munoz C., Arnold J.M.O. Interaction of citrus juices with felodipine and nifedipine. Lancet. 337:1991;268-269.
29. Edgar B., Bailey D.G., Bergstrand R., Johnsson G., Regardh C.G. Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics of felodipine and its potential clinical relevance. Eur. J. Clin. Pharmacol. 42:1992;313-317.
30. Oritz de Montellano PR, Reich NO. Inhibition of cytochrome P450 enzymes. In: Oritz de Montellano PR, editor. Cytochrome P-450. New York: Plenum; 1986, p. 273-314.
31. Ioannides-Demos L.L., Christophidis N., Ryan P., Angelis P., Liolios L., McLean A.J. Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases. J. Rheumatol. 24:1997;49-54.
32. Ku Y.M., Min D.I., Flanigan M. Effect of grapefruit juice on the pharmacokinetics of microemulsion cyclosporine and its metabolite in healthy volunteers: does the formulation difference matter? J. Clin. Pharmacol. 38:1998;959-965.
33. Keogh A., Spratt P., McCosker C., Macdonald P., Mundy J., Kaan A. Ketoconazole to reduce the need for cyclosporine after cardiac transplantation. N. Engl. J. Med. 333:1995;628-633.
34. Taniguchi S., Kobayashi H., Ishii M. Treatment of psoriasis by cyclosporine and grapefruit juice. Arch. Dermatol. 132:1996;1249.
35. Emilia G., Longo G., Bertesi M., Gandini G., Ferrara L., Valenti C. Clinical interaction between grapefruit juice and cyclosporine: is there any interest for the hematologist? Blood. 91:1998;362-363.
36. Lee A.J., Chan W.K., Harralson A.F., Buffum J., Bui B.C. The effects of grapefruit juice on sertraline metabolism: an in vitro and in vivo study. Clin. Ther. 21:1999;1890-1899.
37. Bailey D.G., Arnold J.M.O., Bend J.R., Tran L.T., Spence J.D. Grapefruit juice-felodipine interaction: reproducibility and characterization with the extended release drug formulation. Br. J. Clin. Pharmacol. 40:1995;135-140.
38. Lundahl J., Regardh C.G., Edgar B., Johnsson G. Relationship between time of intake of grapefruit juice and its effect on pharmacokinetics and pharmacodynamics of felodipine in healthy subjects. Eur. J. Clin. Pharmacol. 49:1995;61-67.
39. Libersa C.C., Brique S.A., Motte K.B., Caron J.F., Guedon-Moreau L.M., Humbert L.et al. Dramatic inhibition of amiodarone metabolism induced by grapefruit juice. Br. J. Clin. Pharmacol. 49:2000;373-378.
40. Takanaga H., Ohnishi A., Matsuo H., Sawada Y. Inhibition of vinblastine efflux mediated by P-glycoprotein by grapefruit juice components in caco-2 cells. Biol. Pharm. Bull. 21:1998;1062-1066.
41. Lilja J.J., Kivisto K.T., Neuvonen P.J. Duration of effect on grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin. Clin. Pharmacol. Ther. 68:2000;384-390.
42. Di Marco M.P., Edwards D.J., Wainer I.W., Ducharme M.P. The effect of grapefruit juice and seville orange juice on the pharmacokinetics of dextromethorphan: the role of gut CYP3A and P-glycoprotein. Life Sci. 71:2002;1149-1160.
43. Diekmann H.W., Buhring K.U. The fate of praziquantel in the organism III. Metabolism in rat, beagle dog and rhesus monkey. Eur. J. Drug Metab. Pharmacokinet. 2:1976;107-111.
44. Bailey D.G., Malcolm A.O., Munoz C., Spence J.D. Grapefruit juice-felodipine interaction: mechanism, predictability and effect of naringin. Clin. Pharmacol. Ther. 53:1993;637-642.
45. Buhring K.U., Diekmann H.W., Muller H., Garbe A., Nowak H. Metabolism of praziquantel in man. Eur. J. Drug Metab. Pharmacokinet. 3:1978;179-190.